Arbutus Announces New Data on AB-729 and AB-836 Programs with Presentation of Five Abstracts at the EASL International Liver Congress™ 2021 - All Selected for Best of ILC™
June 26, 2021 07:15 ET
|
Arbutus Biopharma Corporation
AB-729, dosed at 60 mg every 8 weeks, achieved a mean HBsAg decline of -1.87 log10 IU/mL at week 44, comparable to 60 mg dosed every 4 weeks AB-729 resulted in HBsAg declines below 100 IU/ml in 75%...
Arbutus Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver Congress in June
June 02, 2021 07:30 ET
|
Arbutus Biopharma Corporation
Conference Call and Webcast to discuss the new data being presented at EASL scheduled for 8:00 AM ET, Monday, June 28, 2021 WARMINSTER, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma...
Arbutus to Participate in Upcoming Investor Conferences
May 26, 2021 08:00 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with...
Arbutus Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 05, 2021 07:30 ET
|
Arbutus Biopharma Corporation
AB-729, Arbutus’ proprietary subcutaneously delivered RNAi agent, continues to demonstrate robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B...
Arbutus to Report First Quarter 2021 Financial Results and Provide Corporate Update
April 28, 2021 08:00 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with...
Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement
April 01, 2021 07:30 ET
|
Arbutus Biopharma Corporation
Collaboration formed to accelerate the discovery of novel oral inhibitors targeting the SARS-CoV-2 nsp5 main protease for the treatment of COVID-19 and potential future coronavirus outbreaks ...
Arbutus Receives Regulatory Approval to Initiate a Phase 1a/1b Clinical Trial with AB-836, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B Infection
March 16, 2021 07:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., March 16, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with...
Arbutus Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update
March 04, 2021 07:30 ET
|
Arbutus Biopharma Corporation
AB-729, Arbutus’ proprietary subcutaneously delivered RNAi agent, demonstrates robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV) with...
Arbutus to Participate at H.C. Wainwright Global Life Sciences Conference
March 02, 2021 08:00 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with...
Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus
February 26, 2021 07:30 ET
|
Arbutus Biopharma Corporation; Assembly Biosciences, Inc.
Trial will evaluate Assembly’s core inhibitor candidate, vebicorvir, with Arbutus’ RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy SOUTH SAN FRANCISCO, Calif., and WARMINSTER,...